Clinical Trial Update: Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated mapatumumab in combination with bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma. The study status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Mapatumumab (mapatumumab)
• Velcade (bortezomib)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED